<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01795105</url>
  </required_header>
  <id_info>
    <org_study_id>031-KOA-1101n</org_study_id>
    <nct_id>NCT01795105</nct_id>
  </id_info>
  <brief_title>ABF Tourette's Disorder Post Marketing Surveillance Study</brief_title>
  <official_title>Post-Marketing Surveillance of Safety and Efficacy of Abilify® Tablets in Korean Patients With Tourette's Disorder Under the &quot;New Drug Re-Examination&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Korea Otsuka Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Korea Otsuka Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Post-Marketing Surveillance study of Abilify® tablets in accordance with Korean
      regulations on New Drug Re-examination (i.e. New Drug Re-examination Standards: KFDA
      Notification No. 2010-94 dated 27 December 2010).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be conducted in a prospective, single-arm, multi-center format. As this study
      is observational in nature, the patient's follow-up is not prescriptive in nature and must be
      left up to the judgment of the physician (investigator), within the period of observation set
      forth in the protocol.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">May 29, 2015</completion_date>
  <primary_completion_date type="Actual">May 29, 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency (n) of Subjects With Adverse Event</measure>
    <time_frame>Follow-up at least once from baseline to 6 weeks and at least 12weeks</time_frame>
    <description>Frequency (n) and Percentage(%) of subjects with Adverse event</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Change in the TS-CGI(Tourette's Syndrome-Clinical Global Impression-Improvement)</measure>
    <time_frame>at least 6, 12 weeks interval from baseline</time_frame>
    <description>Mean change in the TS-CGI from baseline to next visit(at least 6, 12 weeks interval from baseline) post-treatment
*TS-CGI scale 0=Not assessed
Normal, not at all ill
Borderline ill
Mildly ill
Moderately ill
Markedly ill
Severely ill
Extremely ill</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">692</enrollment>
  <condition>Tourette's Disorder</condition>
  <arm_group>
    <arm_group_label>Aripiprazole (Abilify® Tablets/Abilify® ODT)</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Pediatric patients 6 to 18 years of age with Tourette's Disorder according to the approved
        product market authorization
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pediatric patients 6 to 18 years of age with Tourette's Disorder

          -  Patients who are prescribed Abilify® treatment as per investigator's medical judgment.

          -  Patients who gave written authorization to use their personal and health data

          -  Patients starting Abilify® treatment after agreement is in place

        Exclusion Criteria:

          -  Patients with known hypersensitivity to Aripiprazole or any excipients of Abilify®

          -  Patients who have been treated with Abilify®

          -  Patients with rare hereditary problems of galactose intolerance, the lapp lactase
             deficiency, or glucose-galactose malabsorption

          -  Patients with score 0(Not assessed) or 1(Normal, not at all ill) in the TS-CGI-S

          -  Patients participating in other clinical trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Inha University Hospital</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chonbuk National University Hospital</name>
      <address>
        <city>Jeonju</city>
        <zip>561-712</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>131-795</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <study_first_submitted>January 31, 2013</study_first_submitted>
  <study_first_submitted_qc>February 17, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 20, 2013</study_first_posted>
  <results_first_submitted>January 14, 2018</results_first_submitted>
  <results_first_submitted_qc>January 4, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">April 1, 2019</results_first_posted>
  <last_update_submitted>January 4, 2019</last_update_submitted>
  <last_update_submitted_qc>January 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tourette Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 28, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/05/NCT01795105/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Aripiprazole (Abilify® Tablets/Abilify® ODT)</title>
          <description>Pediatric patients 6 to 18 years of age with Tourette’s Disorder
Patients who are prescribed Abilify® Tablets/Abilify® ODT treatment as per investigator’s medical judgment.
Dose: Aripiprazole (Abilify® Tablets 2mg, 5mg, 10mg, 15mg, Abilify® ODT 10mg, 15mg)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="692"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="648"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Aripiprazole (Abilify® Tablets/Abilify® ODT)</title>
          <description>Pediatric patients with Tourette syndrome aged 6-18 years who were administered with Aripiprazole (Abilify® Tablets/Abilify® ODT) according to the approved dosage.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="648"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>&gt;=6 years and &lt;12 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="648"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="449"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=12 years and &lt;18 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="648"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="199"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>Sex information of 1patient haven't been examined although we asked inversigater to resolve the query.So, it is missing value.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="647"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="114"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="533"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Frequency (n) of Subjects With Adverse Event</title>
        <description>Frequency (n) and Percentage(%) of subjects with Adverse event</description>
        <time_frame>Follow-up at least once from baseline to 6 weeks and at least 12weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aripiprazole Main Surveillance</title>
            <description>Patients who were given Abilify Tablet or Abilify OD Tablet for at least 6 weeks or longer.</description>
          </group>
          <group group_id="O2">
            <title>Aripiprazole Long-term Surveillance</title>
            <description>Patients who were given Abilify Tablet or Abilify OD Tablet for at least 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency (n) of Subjects With Adverse Event</title>
          <description>Frequency (n) and Percentage(%) of subjects with Adverse event</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="648"/>
                <count group_id="O2" value="233"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of patients reported for AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of patients reported for ADR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in the TS-CGI(Tourette's Syndrome-Clinical Global Impression-Improvement)</title>
        <description>Mean change in the TS-CGI from baseline to next visit(at least 6, 12 weeks interval from baseline) post-treatment
*TS-CGI scale 0=Not assessed
Normal, not at all ill
Borderline ill
Mildly ill
Moderately ill
Markedly ill
Severely ill
Extremely ill</description>
        <time_frame>at least 6, 12 weeks interval from baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aripiprazole Main Surveillance</title>
            <description>Patients who were given Abilify Tablet or Abilify OD Tablet for at least 6 weeks or longer.</description>
          </group>
          <group group_id="O2">
            <title>Aripiprazole Long-term Surveillance</title>
            <description>Patients who were given Abilify Tablet or Abilify OD Tablet for at least 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in the TS-CGI(Tourette's Syndrome-Clinical Global Impression-Improvement)</title>
          <description>Mean change in the TS-CGI from baseline to next visit(at least 6, 12 weeks interval from baseline) post-treatment
*TS-CGI scale 0=Not assessed
Normal, not at all ill
Borderline ill
Mildly ill
Moderately ill
Markedly ill
Severely ill
Extremely ill</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="589"/>
                <count group_id="O2" value="233"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>at the first visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.31" spread="0.81"/>
                    <measurement group_id="O2" value="4.34" spread="0.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>at the last visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.73" spread="0.83"/>
                    <measurement group_id="O2" value="2.66" spread="0.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean change in the TS-CGI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.58" spread="0.95"/>
                    <measurement group_id="O2" value="-1.69" spread="0.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Aripiprazole (Abilify® Tablets/Abilify® ODT)</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="648"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neuritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="648"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="648"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="648"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="648"/>
              </event>
              <event>
                <sub_title>Mouth dry</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="648"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="648"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="648"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="648"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="648"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="648"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Weight increase</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="648"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Extrapyramidal disorder</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="648"/>
              </event>
              <event>
                <sub_title>Hyperkinesia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="648"/>
              </event>
              <event>
                <sub_title>Hypertonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="648"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="648"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="648"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="648"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="648"/>
              </event>
              <event>
                <sub_title>Appetite increased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="648"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="648"/>
              </event>
              <event>
                <sub_title>Apathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="648"/>
              </event>
              <event>
                <sub_title>Nervousness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="648"/>
              </event>
              <event>
                <sub_title>Emotional liability</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="648"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="648"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="648"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="648"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="648"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jeong, Hyo-Won</name_or_title>
      <organization>KoreaOtsukaPharma</organization>
      <email>jhw0159@otsuka.co.kr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

